Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
210 hedge funds and large institutions have $1.11B invested in Meridian Bioscience Inc in 2022 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 62 increasing their positions, 68 reducing their positions, and 17 closing their positions.
276% more call options, than puts
Call options by funds: $5.95M | Put options by funds: $1.58M
176% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 17
33% more capital invested
Capital invested by funds: $836M → $1.11B (+$279M)
17% more funds holding
Funds holding: 180 → 210 (+30)
9% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 68
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Impactive Capital
New York City,
New York
|
+$95.3M |
| 2 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$4.7M |
| 3 |
VLKIM
Van Lanschot Kempen Investment Management
Amsterdam,
Netherlands
|
+$4.16M |
| 4 |
Aviva
London,
United Kingdom
|
+$2.05M |
| 5 |
EIP
Epoch Investment Partners
New York
|
+$1.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$23M |
| 2 |
AI
Acuitas Investments
Seattle,
Washington
|
-$6.74M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
-$5.07M |
| 4 |
CEI
Clark Estates Inc
New York
|
-$4.49M |
| 5 |
RA
Royce & Associates
New York
|
-$4.25M |
VIVO Hedge Fund Activity: Q1 2022 in Review
210 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q1 2022, worth a combined $1.11B — up 33% from $836M a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new VIVO positions and 17 closed out — a net gain of 30 holders — while 62 added to existing stakes and 68 trimmed.
The largest buyer was Impactive Capital, adding an estimated $95.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $23M sold.
- 210 institutional investors held Meridian Bioscience Inc (VIVO) as of Q1 2022, up from 180 in Q4 2021.
- Funds reported $1.11B of Meridian Bioscience Inc stock for Q1 2022, up 33% quarter-over-quarter.
- 47 funds opened new Meridian Bioscience Inc positions in Q1 2022 and 17 closed out, a net change of +30 holders.
- The largest Meridian Bioscience Inc buyer in Q1 2022 was Impactive Capital, an estimated $95.3M added.
- The largest Meridian Bioscience Inc seller in Q1 2022 was Deerfield Management, an estimated $23M sold.
Based on aggregated 13F filings for Q1 2022.